Biologic Lutikizumab Didn’t Seem to Improve Knee Osteoarthritis in a Recent Trial
Despite promising results from an earlier trial, lutikizumab — a drug that blocks proteins tied to inflammation — did not hold up in a phase II trial of patients with knee osteoarthritis (OA). The earlier study, a phase I trial published…
Continue reading